100 results about "Strontium ranelate" patented technology

Disclosed are therapeutic oral compositions useful in the treatment of a variety of oral disorders, in which the composition can provide blockage of dentinal tubes, while at the same time provide antibacterial and anti-caries efficacy. The compositions include arginine in free or salt form, a mucoadhesive polymer, and at least one component selected from pyrophosphates, zinc salts, potassium salts, strontium salts, and mixtures thereof.

The invention provides a medical compound for treating osteoporosis which is characterized in that the invention contains strontium ranelate and bisphosphonate. Animal experiments indicate that the invention achieves the unexpected effect for treating the osteoporosis. The osteoporosis is a bone disease of the whole body characterized by the low bone mass and the degeneration of the micro structure of the bone organization, companying with the enhancement of the bone fragility and easy happened bone broken for which no ideal treatment medicine exists in the clinic. The bisphosphonate of the invention comprises alendronate, risedronate sodium, ibandronate, pamidronate, Etidronate, disodium clodronate and zoledronic acid, etc. In the invention, the dosage of the bisphosphonate is greatly reduced, which can effectively reduce the happening of side effects and is convenient to use the medicine.

The invention relates to a medicinal composition containing strontium salts and vitamin D derivatives. Mixed with auxiliary materials acceptable on pharmacy, the medicinal composition of the invention can be prepared into oral formulations such as particulate granules, common tablets, chewable tablets, dispersible tablets, orally disintegrating tablets, effervescent tablets, buccal tablets, capsules, softgels, sustained release tablets, sustained release capsules, oral solutions, syrups, etc., and can be used to prevent and treat various primary or secondary osteoporosis.

A composite medicine and its packed composition for treating the osteoporosis of the woman after manopause contains strontium ranelate or its hydrate, VD and pharmacologically acceptable additives proportionally.

The invention relates to a method for determining strontium calcium barium in strontium carbonate. The method comprises the following steps: (1) preparing an ammonia-ammonium chloride buffer solution; (2) preparing and calibrating a 0.02mol / L EDTA standard solution; (3) preparing a 0.1% PAN indicator solution; (4) preparing a 0.02mol / L copper standard solution; (5) preparing an acetate-sodiumacetate buffer solution; (6) preparing and calibrating a potassium permanganate standard liquid; (7) preparing and calibrating a 0.01 mol / L sodium hyposulfite standard solution according to a routine method; (8) dissolving a sample, carrying out a dry filtering and collecting a filtrate; (9) carrying out capacity analysis of a. analysis and content calculation on strontium, b. analysis and content calculation on calcium, and c. analysis and content calculation on barium. The determination method of the invention is simply operated, has an obvious titration end, reduces time for determining strontium calcium barium in strontium carbonate and increases determination accuracy.

The invention relates to the finding that very favorable pharmacokinetic characters are obtained by combining two strontium salts in one pharmaceutical composition. The present invention relates in one aspect to a pharmaceutical composition comprising at least two strontium salts for use as a medicament, and in particular for the treatment and prevention of bone disorders such as osteoporosis. The composition preferably comprises strontium carbonate and strontium chlorides. Further included may be a vitamin D compound, preferably vitamin D₃.

The invention relates to a new preparation method of strontium ranelate heptahydrate. The products produced by the method have water content of 19.0 per cent to 20.4 per cent and the relevant substances are lower than 0.5 per cent. The strontium ranelate heptahydrate produced by the method is stable under room temperature, has little water content differences between batches and is kept for a long time under natural environment with unchangeable moisture, content and relevant substances. The method is characterized in that: (1) the reflux of the 2-[N, N- 2(carboxymethyl)amino]-3-cyano-group-4-thiopheneacetic-5-carboxylic acid tetra ester (b) is carried out in the proper sodium hydroxide aqueous solution of alcohol for 5h to 6h and the pH value is kept over 10 during hydrolysis; (2) the ethanol of 20 per cent to 60 per cent is added and then the strontium chloride aqueous solution with 2times to 2.5times molal weight is directly added, precipitates the crystal, is filtered and dried; (3) water is added to carry out the reflux and the little salt packed in the crude product is removed, and the product is collected through heat filtration. The invention discloses the drug combination containing the strontium ranelate heptahydrate which is used for the treatment of osteoporosis of women after menopause.

The invention discloses a drug composite to promote the stability of strontium ranelate in the preparation. The invention is characterized in that after the effective dosage of the strontium ranelate for treatment is mixed with medicinal excipients, various dosage forms are produced by adding stabilizer. The dosage of the stabilizer refers to the dosage scope of excipients proscribed in the pharmacopoeia. The experiments and studies determine that the weight percentage of the stabilizer in the drug composite is 0.01-5 percent, which is preferred as 0.01-2 percent. The invention with a simple and unique way solves the color change problem of appearance of strontium ranelate or the problem of material increasing resulting from the excipients like citric acid, aspartame and saccharin sodium contained in the preparation; under the condition of not changing the structure of the strontium ranelate, a certain dosage of stabilizer is added into the excipients to achieve the purpose of the stability of the strontium ranelate. The method simplifies the process and saves the cost, and is more suitable for large-scale industrial production.

The invention discloses a method for preparing strontium ranelate, which comprises the following steps of: 1, preparing diethyl acetonedicarboxylate, namely adding chlorosulfonic acid into a reaction kettle, adding anhydrous citric acid into the reaction kettle, dripping ethanol into the reaction kettle, adding magnesium sulfate into an organic layer for drying, and filtering to obtain the diethyl acetonedicarboxylate; 2, preparing 5-amino-4-cyano-2-(ethoxycarbonyl)-3-thiopheneacetic acid ethyl ester, namely adding the diethyl acetonedicarboxylate, propane dinitrile and water into the reaction kettle, centrifuging and drying; 3, preparing ethyl 5-amino-4-cyano-3-(2-ethoxy-2-oxoethyl)thiophene-2-carboxylate; and 4, preparing the strontium ranelate which has the purity of over 99.8 percent,the content of a single impurity of less than 0.1 percent and the yield of 70 percent. The strontium ranelate prepared by the method has high product purity, a few single impurity and low manufacturing cost.

The present invention relates to a preparation method of the substituted thiophene formate as shown in formula (I), wherein the R₁, R₂, R₃ and R₄ can be the same and can be different; and the R₁, R₂, R₃ and R₄ respectively represent the alkyl of the straight chain or branched-chain of C₁-C₁₀, or the aryl of C₆-C₁₂, wherein the aryl can be replaced with 1 to 4 substituted bases. The present invention provides a novel method of preparing the substituted thiophene formate as shown in formula (I); the method is more economical and less harmful to the environment. The compound of the formula (I) produced in the present invention can be used for the synthesis of strontium ranelate.

The invention relates a production method of granular anhydrous strontium chloride. The method has the advantages of energy saving, environmental friendliness, simple process, convenience in operation and stable quality. The production method comprises the following steps: a. reacting strontium carbonate with hydrochloric acid to form strontium chloride solution; b. carrying out impurity removal and filtration treatment on the strontium chloride solution; c. evaporating and concentrating treated clear strontium chloride solution with drying hot tail air to increase concentration of the solution to 40-44 Baume degrees, and simultaneously absorbing anhydrous strontium chloride dust out of the hot tail air; and d. pumping the concentrated solution to a fluidized bed, spraying and granulating as well as simultaneously drying by the drying hot air of the fluidized bed, wherein the average particle size of the granulation product is controlled to be between 2 mm and 5 mm and the drying hot air at the equipment outlet can be used in the step c. Through verification, the energy consumption of the production method is 60% that of the existing technical scheme, the product has water content of 0.1-0.3% and the product can be stored for at least 6 months, and the corrosion to equipment is reduced.

The invention discloses a making method of ranimycin strontium tetrahydrate, which comprises the following steps: adopting rough product of ranimycin strontium tetrahydrate with content over 80% as formula (I) as raw material; suspending in the water; adjusting pH value under indoor temperature or heating condition through acid until dissolving completely; obtaining the supernatant; washing through organic solvent; filtering; adjusting pH value through alkaline to neutral alkali-bias; stirring; filtering; drying to obtain the product with stable property.

The present disclosure relates to a hair treatment agent for reducing and/or avoiding bleeding out and/or fading of artificially produced hair colours with a pH in a range of from about 3.5 to about 5 containing—relative to the total quantity of hair treatment agent—

• a) from about 0.01 to about 10 wt. % of a polyvalent metal salt, wherein the metal salt is selected from the group of strontium salts, zirconium salts, hafnium salts, titanium salts, tin salts, aluminium salts, bismuth salts, lanthanum maleate, lanthanum chloride and mixtures thereof and
• b) from about 0.01 to about 10 wt. % of an organic acid selected from the group of tartaric acid, citric acid, maleic acid, fumaric acid, salicylic acid, lactic acid, malic acid, amino acids and mixtures thereof.

The invention discloses a dry suspension containing strontium ranelate. The dry suspension contains the following components by weight ratio: 50-90 per cent of lactose, or xylitol, or mannite or 50-90 per cent of the combination of lactose, xylitol, mannite; 10-49 per cent of strontium ranelate; 0.1-10 per cent of correctives; 0.1-10 per cent of colorant; and 1-20 per cent of adhesive. With good stability, the dry suspension containing strontium ranelate disclosed in the invention is used for curing and preventing the menopausal osteoporosis.

The invention provides double antiallergic toothpaste containing paeonol and strontium salt. The double antiallergic toothpaste is prepared from an antiallergic component and a base material component, wherein the antiallergic component is prepared from 1.0 to 3.0 percent by weight of strontium salt and 0.2 to 1.0 percent by weight of paeonol; the base material component is prepared from a humectant, an abrasive, a surfactant, a thickening agent, a sweetening agent, perfume, pigment, a paste stabilizer, a preservative and water. The paeonol and the strontium salt are added into a toothpaste base material in a specific mixture ratio in a supplemental way, and act on dental nerve in a cooperative manner, so that the double antiallergic toothpaste has a remarkable antiallergic effect.

Composition preparation or pharmaceutical composition related to the invention contains (a) PPAR regulator, (b), strontium salt as active component, which is or is not combined with one or more acceptable excipients in pharmacy, the active component being used at the same, in a separated way or in sequence; the composition is used to improve, prevent or treat osteoporosis caused by prevention or treatment of PPAR regulator or diseases prevented or treated by PPAR regulator and groups with osteoporosis.

The invention relates to high-purity strontium ranelate and a preparation method thereof. The high-purity strontium ranelate is characterized in that the purity of the strontium ranelate is not lower than 99.5%, and a single impurity is not greater than 0.4%. The high-purity strontium ranelate is suitable for medicinal use and can effectively control the quality of products. The invention also relates to a medicine composition prepared by mixing a medicinal carrier and the high-purity strontium ranelate.

The invention relates to the finding that very favorable pharmacokinetic characters are obtained by combining two strontium salts in one pharmaceutical composition. The present invention relates in one aspect to a pharmaceutical composition comprising at least two strontium salts for use as a medicament, and in particular for the treatment and prevention of bone disorders such as osteoporosis. The composition preferably comprises strontium carbonate and strontium chlorides. Further included may be a vitamin D compound, preferably vitamin D₃.

The invention discloses a preparation method of strontium ranelate key intermediate 3-ketoglutaric acid diethyl (dimethyl) ester. The method comprises the steps of firstly adding a solvent into a reactor, cooling, putting a solid super acidic catalyst, then putting citric acid monohydrate, slowly heating, performing a thermal reaction, heating until the thermal reaction ends after no obvious bubbles exist, filtering to obtain filtrate, recycling a filter cake as a catalyst, performing solvent recovery on the filtrate, adding into ice water, extracting by adding dichloromethane, washing an extract by using a sodium bicarbonate aqueous solution, water and a saturated saline solution in sequence, and performing reduced pressure distillation to obtain a product, wherein the catalyst is solid super-acid; reaction conditions are as follows: the reaction temperature is between -20 DEG C and 60 DEG C, and the reaction time is 2-12 hours (the sum of the heat preservation time). The process disclosed by the invention does not use any liquid acid catalyst, is mild in reaction, short in steps and simple and convenient in operation, can not cause acid wastewater discharge, and is green and environment-friendly.